1st International Conference on Human &amp; Translational Immunology

Hope, Jennifer L.; Pulendran, Bali; Schoenberger, Stephen P.; Katsikis, Peter D.

doi:10.1038/ni.3635

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet despite such understanding of the functions elicited by distinct DC subsets (5), our knowledge of the DC subset or subsets that promote the most potent antitumor responses in humans is less clear. We previously reported that migratory skin CD5 + DCs, which we found on a subset of DC2s, prime inflammatory T H cells and multifunctional CTLs more effectively than their CD5 -DC2 counterparts (18,20). Their increased frequency in inflammatory settings led us to hypothesize that these cells are predominantly involved in the antitumor response.…”

Section: Resultsmentioning

confidence: 75%

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

Roussak

et al. 2023

Science

View full text Add to dashboard Cite

The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for antitumor responses and effective immune checkpoint blockade (ICB) therapy. Here, we show that human CD1c + CD5 + DCs are reduced in melanoma-affected lymph nodes, with CD5 expression on DCs correlating with patient survival. Activating CD5 on DCs enhanced T cell priming and improved survival after ICB therapy. CD5 + DC numbers increased during ICB therapy, and low interleukin-6 (IL-6) concentrations promoted their de novo differentiation. Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5 hi T helper and CD8 + T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5 + DCs are an essential component of optimal ICB therapy.

show abstract

Section: Resultsmentioning

confidence: 75%